CYPRUS MIRROR
reading time: 6 min.

Pfizer/BioNTech vs AstraZeneca vs Sinovac: “Highest antibody in Pfizer/Biontech vaccine”

Pfizer/BioNTech vs AstraZeneca vs Sinovac: “Highest antibody in Pfizer/Biontech vaccine”

Cypriot volunteer researchers; Sinovac, Pfizer/BioNTech, and AstraZeneca published research comparing antibody levels between coronavirus vaccines and post-single booster vaccines. The study entered the literature as the first study in the world to evaluate these three vaccines longitudinally simultaneously.

Publish Date: 14/02/22 08:25
reading time: 6 min.
Pfizer/BioNTech vs AstraZeneca vs Sinovac: “Highest antibody in Pfizer/Biontech vaccine”
A- A A+

In cooperation with the Ethics Hospital Biochemistry Laboratory, volunteer Cypriot researchers; Sinovac, Pfizer/BioNTech and AstraZeneca His research on the comparison of coronavirus vaccines and antibody levels after a single dose booster vaccine has been published in the prestigious health journal "The Lancet Microbe".

The study entered the literature as the first study in the world to evaluate these three vaccines longitudinally simultaneously.

The study, which covers the coronavirus vaccines applied in the TRNC, was carried out by researchers, Biostatistics Specialist Burç Barın, Biochemist Ulus Kasap, Dr. Ferda Selcuk, Dr. Ender Volkan and Dr. Özge Uluçkan held it between 1 March – 30 September 2021.

The main purpose of the study was explained as "comparison of 'immunoglobulin G' antibody levels after two doses of Sinovac, Pfizer/BioNTech and AstraZeneca vaccines and relative examination of the change over a 3-month period".

FOR THE FIRST TIME IN THE WORLD, THREE VACCINES ARE EVALUATED SIMULTANEOUSLY

Within the scope of the study, for the first time in the world, three vaccines were evaluated longitudinally simultaneously, while post-vaccine side effects were examined according to age groups, and the effect of Sinovac or BioNTech booster dose on antibody levels after two doses of Sinovac vaccine was evaluated.

INDEPENDENT RESEARCH

In the study, Ulus Kasap, director of the Ethics Hospital Biochemistry Laboratory, and his team undertook the majority of welcoming the participants, blood collection and antibody analysis; The study was carried out completely independently with the cooperation of volunteer scientists and business people who supported the study.

413 VOLUNTEERS ATTENDED THE RESEARCH AS DONORS

While it was stated that a total of 413 volunteers participated in the prospective, population-based study, which was evaluated many times over time, it was emphasized that blood samples were taken 1 month and 3 months after the second dose from the people in the vaccine groups, and personal health information and vaccine side effects were collected through the study questionnaire.

RESULTS… PFIZER/BIONTECH VACCINE GAVE THE HIGHEST ANTIBODY RESPONSE

According to the research, the highest rate and level of antibody response to the vaccine was seen with the Pfizer/BioNTech vaccine, followed by AstraZeneca and finally Sinovac.

SINOVAC SHOWED THE FASTEST DECREASE IN ANTIBODY LEVEL

On the other hand, it was revealed that Sinovac group showed the fastest mean decrease in antibody level in the 3-month time frame after the second dose, followed by AstraZeneca and finally Pfizer/BioNTech.

AGES 60 OR OVER, ANTIBODY RATE 3 MONTHS AFTER THE SECOND DOSAGE 100 PERCENT AT PFIZER

It was stated that in people aged 60 and over, 3 months after the second dose, the rate of measurable (positive) active antibodies in the blood was 100 percent in the Pfizer/BioNTech group, 90 percent in the AstraZeneca group, and 60 percent in the Sinovac group.

“HIGHER AGE GROUP MEN HAVE LOWER ANTIBODY LEVELS”

According to the study, in addition to differences between vaccines, it was noted that lower antibody levels were observed in higher age groups and time after vaccination in males.

SIDE EFFECT… ASTRAZENECA RANKED FIRST

The rates of mild and moderate side effects were also evaluated in the study.

According to this; Side effects were detected in 50 percent in the Sinovac group, 77 percent in the Pfizer/BioNTech group, and 95 percent in the AstraZeneca group (after the first dose).

On the other hand, it was stated that the side effects seen after a single dose of Pfizer/BioNTech supplementation on Sinovac were similar to the side effects and rates seen in Pfizer/BioNTech given as the main vaccine, while it was noted that no serious side effects were reported after the Pfizer/BioNTech supplement dose.

ANTIBODY LEVELS AFTER SUPPLEMENT DOSES ALSO EVALUATED

In the study, antibody levels were also evaluated 1 month after the booster dose in a subset of the subset who received a booster dose of Sinovac or Pfizer/BionTech 6 months after receiving two doses of Sinovac vaccine.

“ANTIBODY INCREASED WITH PFIZER SUPPLEMENT ON SINOVAC, A 'MODE' INCREASED AT SINOVAC SUPPLEMENT”

According to this; A single dose of Pfizer/BioNTech supplementation over two doses of Sinovac produced a steady and significant increase in antibody levels in all participants, while a single dose of Sinovac supplementation over two doses of Sinovac produced a much more 'modest' increase in antibody levels.

6 PEOPLE WERE POSITIVE DURING THE WORKING PROCESS, 5 OF them SINOVAC VACCINATION

During the study follow-up, it was stated that 6 people were diagnosed with Coronavirus positive, 5 of 6 people were in the Sinovac group and 1 was in the AstraZeneca group. The last measured antibody levels of 6 people who were diagnosed with coronavirus were negative or in the lower 25% antibody values ​​range. was recorded.

INSTITUTIONS THAT PROVIDE FINANCIAL AND EQUIPMENT SUPPORT TO THE RESEARCH

The research team thanked the study participants, Etik Hospital Biochemistry Laboratory, CCO Solar, Akçaba Communications, JetGaz, Amor Ltd, Dünya IVF Center, Mikrolab and Duolab Biochemistry Laboratories, individual donors and volunteers who contributed financially, employee and/or equipment to the study. He thanked.

To keep up to date with latest Cyprus news

Comments

Attention!
Sending all kinds of financial, legal, criminal, administrative responsibility content arising from illegal, threatening, disturbing, insulting and abusive, humiliating, humiliating, vulgar, obscene, immoral, damaging personal rights or similar content. It belongs to the Member / Members.